Accéder au contenu
Merck

Novel bioactive metabolites of dipyrone (metamizol).

Bioorganic & medicinal chemistry (2011-12-17)
Tobias Rogosch, Christian Sinning, Agnes Podlewski, Bernhard Watzer, Joel Schlosburg, Aron H Lichtman, Maria G Cascio, Tiziana Bisogno, Vincenzo Di Marzo, Rolf Nüsing, Peter Imming
RÉSUMÉ

Dipyrone is a common antipyretic drug and the most popular non-opioid analgesic in many countries. In spite of its long and widespread use, molecular details of its fate in the body are not fully known. We administered dipyrone orally to mice. Two unknown metabolites were found, viz. the arachidonoyl amides of the known major dipyrone metabolites, 4-methylaminoantipyrine (2) and 4-aminoantipyrine (3). They were identified by ESI-LC-MS/MS after extraction from the CNS, and comparison with reference substances prepared synthetically. The arachidonoyl amides were positively tested for cannabis receptor binding (CB(1) and CB(2)) and cyclooxygenase inhibition (COX-1 and COX-2 in tissues and as isolated enzymes), suggesting that the endogenous cannabinoid system may play a role in the effects of dipyrone against pain.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
4-Aminoantipyrine, reagent grade
Sigma-Aldrich
4-Aminoantipyrine, puriss. p.a., reag. Ph. Eur., ≥99%
Supelco
4-Aminoantipyrine, for spectrophotometric det. of H2O2 and phenols, ≥98.0%
Sigma-Aldrich
4-(Methylamino)pyridine, 98%